---
title: Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy
nct_id: NCT02838121
overall_status: COMPLETED
phase: PHASE3
sponsor: Mel Shiuann-Sheng Lee
study_type: INTERVENTIONAL
primary_condition: Prevention of BMD Loss After THR
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02838121.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02838121"
ct_last_update_post_date: 2016-07-20
last_seen_at: "2026-05-12T06:39:27.513Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

**Official Title:** Investigation on the Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy: A Prospective Randomized Clinical Trial

**NCT ID:** [NCT02838121](https://clinicaltrials.gov/study/NCT02838121)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 62
- **Lead Sponsor:** Mel Shiuann-Sheng Lee
- **Collaborators:** Novartis
- **Conditions:** Prevention of BMD Loss After THR, Serum Markers of Bone Turnover, Functional Outcomes
- **Start Date:** 2009-12
- **Completion Date:** 2016-06
- **CT.gov Last Update:** 2016-07-20

## Brief Summary

Periprosthetic bone loss caused by stress-shielding effect, a phenomenon of bone atrophy under mechanical unloading after THR implantation, further compromises the longevity of implant. The prospective randomized study is aimed to investigate the periprosthetic bone loss after primary total hip replacements.

## Detailed Description

This study is a prospective, randomized, open-label clinical trial. The study will be performed in patients after obtaining informed consent. Group assignment is by drawing a sealed envelops based on random table. (1) Group 1: Experimental group 30 cases, Aclasta® (Zoledronic acid 5mg/100ml) is given intravenously on the 4th postoperative day and one year after the total hip replacement, (2) Group 2: Control group, 30 cases, no bisphosphonate is given to the patients. Only the unilateral coxarthrosis will be recruited for the study. Patients will be analyzed with (1) DXA study (2) Clinical assessment (Harris hip score and SF-12) (3) X-ray (4) serum marker of bone turnover. Patients will be scheduled for specified examinations preoperatively, postoperatively 6 weeks, 3 months, 6 months, 12 months, and 24 months.

## Eligibility

- **Minimum age:** 35 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Male or female,between 35 and 85 years of age
2. Indicated for Total hip replacement for various hip diseases
3. Has preoperative DXA study within 3 months before the total hip replacement procedure or willing to receive preoperative DXA study as a baseline comparison
4. Signed written informed consent
5. Standard transgluteal approach for total hip replacement using Zimmer Triology Cup and Versys Fiber Metal Taper Stem with metal to highly cross-linked polyethylene bearing surface

Exclusion Criteria:

1. Any prior use of intravenous bisphosphonate within the last 2 years
2. Uncontrolled seizure disorders associated with falls
3. A history of invasive malignancy of any organ system, treated or untreated, within the past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed
4. Carcinoma in situ of the uterine cervix
5. History of osteogenesis imperfecta, multiple myeloma, or Paget's disease
6. Active primary hyperparathyroidism
7. History of iritis or uveitis
8. Self-reported history of diabetic nephropathy or retinopathy
9. AST or ALT more than twice the upper limit of normal
10. Alkaline phosphatase more than twice the upper limit of normal
11. Serum calcium 2.75 mmol/L (11.0 mg/dL)
12. Baseline renal insufficiency (calculated creatinine clearance 35 ml/min)
13. History of hypersensitivity to bisphosphonates
14. Use of any investigational drug(s) and/or devices within 30 days prior to randomization
15. Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the Protocol or completing the trial per protocol
16. Use of hip protectors
17. With implant or prosthesis on the contralateral hip joint
```

## Arms

- **Aclasta** (EXPERIMENTAL) — Aclasta IV once annual for 2 years
- **Placebo** (PLACEBO_COMPARATOR) — Placebo group

## Interventions

- **Aclasta** (DRUG) — Aclasta once annually for 2 years
- **Placebo** (DRUG) — No IV aclasta

## Primary Outcomes

- **bone mineral density [g/cm2] of the 7 Gruen zones** _(time frame: 5 years)_ — bone mineral density measured by dual energy x-ray absorptiometry
- **bone mineral density change relative to the baseline values of the 7 Gruen zones** _(time frame: 5 years)_ — bone mineral density measured by dual energy x-ray absorptiometry
- **implant loosening or migration** _(time frame: 5 years)_ — check the implant position by serial standard X ray follow-up

## Secondary Outcomes

- **serum alkaline phosphatase** _(time frame: 5 years)_
- **serum calcium level** _(time frame: 5 years)_
- **serum phosphate level** _(time frame: 5 years)_
- **serum osteocalcin level** _(time frame: 5 years)_
- **serum N-telopeptide procollagen level** _(time frame: 5 years)_
- **serum creatinine level** _(time frame: 5 years)_
- **serum alanine aminotransferase level** _(time frame: 5 years)_
- **serum aspartate aminotransferase level** _(time frame: 5 years)_
- **harris hip score** _(time frame: 5 years)_
- **short form-12** _(time frame: 5 years)_
- **University of California Los Angeles Activity Score** _(time frame: 5 years)_

## Locations (1)

- Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chang gung memorial hospital|kweishan|taoyuan|taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02838121.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02838121*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*